{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:13:09Z","timestamp":1789135989922,"version":"build-2803163510"},"reference-count":101,"publisher":"Scientific Scholar","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jor.2020.03.020","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T02:55:09Z","timestamp":1585364109000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Integration of denosumab therapy in the management of giant cell tumors of bone"],"prefix":"10.25259","volume":"22","author":[{"given":"Daniel T.","family":"Miles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Voskuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wood","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel L.","family":"Mayerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Scharschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"issue":"11","key":"10.1016\/j.jor.2020.03.020_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","article-title":"New insights into osteoclastogenic signaling mechanisms","volume":"23","author":"Nakashima","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0004563218759371","article-title":"The bone remodelling cycle","volume":"55","author":"Kenkre","year":"2018","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s10517-014-2605-y","article-title":"Components of the RANK\/RANKL\/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors","volume":"157","author":"Kushlinskii","year":"2014","journal-title":"Bull Exp Biol Med"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","article-title":"Osteocyte control of osteoclastogenesis","volume":"54","author":"O'Brien","year":"2013","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2015.06.002","article-title":"RANK and RANK ligand expression in primary human osteosarcoma","volume":"4","author":"Branstetter","year":"2015","journal-title":"J Bone Oncol"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00223-019-00573-6","article-title":"The role of osteoprotegerin in vascular calcification and bone metabolism: the basis for developing new therapeutics","volume":"105","author":"Rochette","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yexcr.2015.08.001","article-title":"Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL","volume":"338","author":"Marley","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jor.2020.03.020_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5435\/JAAOS-21-02-118","article-title":"Giant cell tumor of bone","volume":"21","author":"Raskin","year":"2013","journal-title":"J Am Acad Orthop Surg"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12094-014-1268-5","article-title":"Giant cell tumour of bone: new treatments in development","volume":"17","author":"L\u00f3pez-Pousa","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jor.2020.03.020_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4081\/rt.2009.e52","article-title":"The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program","volume":"1","author":"Beebe-Dimmer","year":"2009","journal-title":"Rare Tumors"},{"issue":"13","key":"10.1016\/j.jor.2020.03.020_bib19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2217\/fon.15.94","article-title":"Denosumab for the treatment of giant cell tumor of the bone","volume":"11","author":"Brodowicz","year":"2015","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.jor.2020.03.020_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/14737140.2014.901891","article-title":"The multidisciplinary management of giant cell tumor of bone","volume":"14","author":"Ng","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1148\/rg.331125089","article-title":"Giant cell tumor of bone: review, mimics, and new developments in treatment","volume":"33","author":"Chakarun","year":"2013","journal-title":"Radiographics"},{"key":"10.1016\/j.jor.2020.03.020_bib22","first-page":"1","article-title":"Response evaluation of giant-cell tumor of bone treated by denosumab: histogram and texture analysis of CT images [published online ahead of print]","author":"Yi","year":"2018","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.jor.2020.03.020_bib23","series-title":"International Agency for Research on Cancer. WHO Classification of Tumours of Soft Tissue and Bone","year":"2013"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0002-9440(10)64942-5","article-title":"Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-\u03baB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation","volume":"156","author":"Huang","year":"2000","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00428-009-0863-2","article-title":"Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone","volume":"456","author":"Alberghini","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jor.2020.03.020_bib26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.jor.2020.03.020_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1684\/bdc.2011.1398","article-title":"The role of RANK\/RANKL\/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications","volume":"98","author":"Cl\u00e9zardin","year":"2011","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.job.2019.02.002","article-title":"Bone metastasis: interaction between cancer cells and bone microenvironment","volume":"61","author":"Hiraga","year":"2019","journal-title":"J Oral Biosci"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2559.2011.03948.x","article-title":"Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone","volume":"59","author":"Balla","year":"2011","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9440(10)63323-8","article-title":"Cathepsin K is the principal protease in giant cell tumor of bone","volume":"165","author":"Lindeman","year":"2004","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.jor.2020.03.020_bib31","first-page":"1529","article-title":"Expression of cathepsin K and tartrate-resistant acid phosphatase is not confined to osteoclasts but is a general feature of multinucleated giant cells: systematic analysis","volume":"52","author":"Park","year":"2013","journal-title":"Rheumatol (United Kingdom)"},{"issue":"7","key":"10.1016\/j.jor.2020.03.020_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/gcc.20667","article-title":"Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations","volume":"48","author":"Gorunova","year":"2009","journal-title":"Gene Chromosome Canc"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib34","first-page":"133","article-title":"Telomeric associations","volume":"16","author":"Schwartz","year":"1990","journal-title":"Appl Cytogenet J Assoc Cytogenet Technol"},{"key":"10.1016\/j.jor.2020.03.020_bib35","article-title":"Histone H3.3 mutation in giant cell tumor of bone: an update in pathology","author":"Yamamoto","year":"2019","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.jor.2020.03.020_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.humpath.2017.11.020","article-title":"Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone","volume":"73","author":"Yamamoto","year":"2018","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.jor.2020.03.020_bib37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.jor.2020.03.020_bib38","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","article-title":"Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma","volume":"39","author":"Cleven","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/gcc.20656","article-title":"Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis","volume":"48","author":"Moskovszky","year":"2009","journal-title":"Gene Chromosome Canc"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-014-1666-7","article-title":"Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis","volume":"465","author":"Lieveld","year":"2014","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2559.2001.01275.x","article-title":"Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation","volume":"39","author":"Oda","year":"2001","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11999-010-1501-7","article-title":"Giant cell tumor of bone: risk factors for recurrence","volume":"469","author":"Klenke","year":"2011","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/17453670710014815","article-title":"Cement is recommended in intralesional surgery of giant cell tumors A Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years","volume":"79","author":"Kivioja","year":"2008","journal-title":"Acta Orthop"},{"key":"10.1016\/j.jor.2020.03.020_bib44","first-page":"69","article-title":"Ethanol as a local adjuvant for giant cell tumor of bone","volume":"26","author":"Jones","year":"2006","journal-title":"Iowa Orthop J"},{"issue":"5","key":"10.1016\/j.jor.2020.03.020_bib45","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.2106\/JBJS.M.00516","article-title":"Liquid nitrogen or phenolization for giant cell tumor of bone?: a comparative cohort study of various standard treatments at two tertiary referral centers","volume":"96","author":"van der Heijden","year":"2014","journal-title":"J Bone Jt Surg"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case\u2013control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jor.2020.03.020_bib47","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur J Canc"},{"issue":"12","key":"10.1016\/j.jor.2020.03.020_bib48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1302\/0301-620X.93B12.27663","article-title":"Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone?","volume":"93-B","author":"Gaston","year":"2011","journal-title":"J Bone Joint Surg Br"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/17453674.2012.711193","article-title":"Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones","volume":"83","author":"van der Heijden","year":"2012","journal-title":"Acta Orthop"},{"issue":"5","key":"10.1016\/j.jor.2020.03.020_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The clinical approach toward giant cell tumor of bone","volume":"19","author":"van der Heijden","year":"2014","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.jor.2020.03.020_bib51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1148\/radiographics.21.5.g01se251283","article-title":"Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation","volume":"21","author":"Murphey","year":"2001","journal-title":"Radiographics"},{"key":"10.1016\/j.jor.2020.03.020_bib52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00432-008-0370-x","article-title":"Giant cell tumor of bone: treatment and outcome of 214 cases","volume":"134","author":"Balke","year":"2008","journal-title":"J Canc Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib53","first-page":"1","article-title":"The role of denosumab in the modern treatment of giant cell tumor of bone","volume":"5","author":"Thornley","year":"2017","journal-title":"J Bone Jt Surg Rev"},{"issue":"11","key":"10.1016\/j.jor.2020.03.020_bib54","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1302\/0301-620X.97B11.35326","article-title":"Does pathological fracture affect the rate of local recurrence in patients with a giant cell tumour of bone?","volume":"97-B","author":"Salunke","year":"2015","journal-title":"Bone Joint Lett J"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1302\/0301-620X.80B1.0800043","article-title":"Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up","volume":"80","author":"Siebenrock","year":"1998","journal-title":"J Bone Joint Surg Br"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib56","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2009.07.1704","article-title":"The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone","volume":"78","author":"Ruka","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.jor.2020.03.020_bib57","doi-asserted-by":"crossref","DOI":"10.4132\/jptm.2016.12.21","article-title":"Denosumab-treated giant cell tumor of the bone mimicking low-grade central osteosarcoma [published online ahead of print february 12 2018]","volume":"52","author":"Wu","year":"2018","journal-title":"J Pathol Transl Med"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib58","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bone.2009.08.010","article-title":"The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro","volume":"45","author":"Mitrofan","year":"2009","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2011.02.003","article-title":"Bisphosphonates in oncology","volume":"49","author":"Coleman","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect Tissue Res"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib61","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Canc"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3892\/ol.2012.1036","article-title":"Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates","volume":"5","author":"Yu","year":"2013","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.jor.2020.03.020_bib63","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0280","article-title":"Adjuvant zoledronic acid in high\u2010risk giant cell tumor of bone: a multicenter randomized phase II trial","volume":"24","author":"Lipplaa","year":"2019","journal-title":"Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.jor.2020.03.020_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-005-2419-8","article-title":"Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?","volume":"92","author":"Holen","year":"2005","journal-title":"Breast Canc Res Treat"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10585-010-9319-y","article-title":"RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells","volume":"27","author":"Akiyama","year":"2010","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"10.1016\/j.jor.2020.03.020_bib68","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","article-title":"The RANK\/RANKL\/OPG triad in cancer-induced bone diseases","volume":"25","author":"Dougall","year":"2007","journal-title":"Canc Metastasis Rev"},{"issue":"12","key":"10.1016\/j.jor.2020.03.020_bib70","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"20","author":"Bekker","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.jor.2020.03.020_bib71","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.jor.2020.03.020_bib72","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.jor.2020.03.020_bib73","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jor.2020.03.020_bib74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.jor.2020.03.020_bib75","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9810","key":"10.1016\/j.jor.2020.03.020_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jor.2020.03.020_bib77","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib78","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Canc"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Canc Treat Rev"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/CCO.0b013e328354c129","article-title":"RANKL, denosumab, and giant cell tumor of bone","volume":"24","author":"Thomas","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.jor.2020.03.020_bib82","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Canc Res"},{"issue":"19","key":"10.1016\/j.jor.2020.03.020_bib83","first-page":"1","article-title":"Articles Denosumab in patients with giant-cell tumour of bone\u00a0: a multicentre , open-label , phase 2 study","volume":"2045","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jor.2020.03.020_bib84","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jor.2020.03.020_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.01.006","article-title":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone ScienceDirect","volume":"59","author":"Traub","year":"2016","journal-title":"Eur J Canc"},{"issue":"9","key":"10.1016\/j.jor.2020.03.020_bib86","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib87","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MPH.0000000000000034","article-title":"Golden bullet\u2014denosumab: early rapid response of metastatic giant cell tumor of the bone","volume":"36","author":"Demirsoy","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"issue":"15","key":"10.1016\/j.jor.2020.03.020_bib88","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.2106\/JBJS.M.01332","article-title":"A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab","volume":"96","author":"Mak","year":"2014","journal-title":"J Bone Jt Surg"},{"key":"10.1016\/j.jor.2020.03.020_bib89","article-title":"Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection","volume":"2013","author":"Agarwal","year":"2013","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib90","first-page":"1","article-title":"Giant cell tumors of the bone: changes in image features after denosumab administration","volume":"17","author":"Oguro","year":"2018","journal-title":"Magn Reson Med Sci"},{"issue":"3","key":"10.1016\/j.jor.2020.03.020_bib91","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jclinpath-2015-203248","article-title":"Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series","volume":"69","author":"Girolami","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jor.2020.03.020_bib92","author":"AMGEN"},{"issue":"16","key":"10.1016\/j.jor.2020.03.020_bib93","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Canc"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib94","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr Blood Canc"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib95","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9967","key":"10.1016\/j.jor.2020.03.020_bib96","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(14)61338-6","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jor.2020.03.020_bib97","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"10.1016\/j.jor.2020.03.020_bib98","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jjco\/hyz004","article-title":"A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610","volume":"49","author":"Urakawa","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jor.2020.03.020_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin Sarcoma Res"},{"issue":"7","key":"10.1016\/j.jor.2020.03.020_bib100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00256-015-2117-5","article-title":"Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy","volume":"44","author":"Matcuk","year":"2015","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jor.2020.03.020_bib101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.jor.2020.03.020_bib102","article-title":"Denosumab in giant cell tumour of bone in the pelvis and sacrum: long-term therapy or bone resection?","author":"Sambri","year":"2019","journal-title":"J Orthop Sci"},{"issue":"9","key":"10.1016\/j.jor.2020.03.020_bib103","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s11999.0000000000000104","article-title":"Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: is there an increased risk of local recurrence?","volume":"476","author":"Scoccianti","year":"2018","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"10.1016\/j.jor.2020.03.020_bib104","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2106\/JBJS.17.00057","article-title":"Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage","volume":"100","author":"Errani","year":"2018","journal-title":"J Bone Jt Surg - Am"},{"issue":"5S","key":"10.1016\/j.jor.2020.03.020_bib105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.6004\/jnccn.2013.0200","article-title":"Updates in the treatment of bone cancer","volume":"11","author":"Biermann","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jor.2020.03.020_bib106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2017.02.021","article-title":"Giant cell tumour of bone in the denosumab era ScienceDirect","volume":"77","author":"Van Der Heijden","year":"2017","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.jor.2020.03.020_bib107","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1302\/0301-620X.101B2.BJJ-2018-0907.R2","article-title":"Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone","volume":"101-B","author":"Puri","year":"2019","journal-title":"Bone Joint Lett J"}],"updated-by":[{"DOI":"10.1016\/j.jor.2020.12.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000}}],"container-title":["Journal of Orthopaedics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972978X20301069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972978X20301069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:04:06Z","timestamp":1789135446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jortho.org\/integration-of-denosumab-therapy-in-the-management-of-giant-cell-tumors-of-bone\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":101,"alternative-id":["S0972978X20301069"],"URL":"https:\/\/doi.org\/10.1016\/j.jor.2020.03.020","relation":{},"ISSN":["0972-978X"],"issn-type":[{"value":"0972-978X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of denosumab therapy in the management of giant cell tumors of bone","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jor.2020.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}